A dedicated and coordinated effort to introduce pneumococcal vaccines will save millions of children's lives

A dedicated effort to introduce pneumococcal vaccines will save millions of children's lives

Vaccine Financing

New, lifesaving pneumococcal conjugate vaccines are now available. Affordable pricing is possible, but the price of new vaccines will be more than pennies per dose. Expanding the pool of funds to pay for these vaccines is one way to ensure that pneumococcal disease is prevented and the lives of children around the world are saved.

The good news is that global immunization funding could be as much as $8 billion for new vaccines over the next 10 years with the advent of two innovative financing mechanisms: International Finance Facility for Immunizations and Advance Market Commitment. IFFIm continues to gain commitments; thus far, eight countries have committed funds: UK, France, Italy, Spain, Sweden, Norway, Brazil and South Africa. The G7 nations agreed upon a pilot AMC and pneumococcal vaccines are one of the candidates for consideration; if pneumococcal vaccines are chosen, as much as $1.5 billion could be earmarked for pneumococcal vaccines.

Global Funds for Immunization could be as much as $8 million.

Global Funds for Immunization could be as much as $8 billion.


The AMC creates incentives for manufacturers to invest in research and development and/or expanding capacity by ensuring demand for vaccines.

For more information on AMC, click here.


IFFIm leverage additional money from international capital markets by issuing bonds of long-term donor commitments.

For more information on IFFIm, click here


Cost-effectiveness analysis has shown that the cost-effectiveness for routine pneumococcal vaccination in low income countries is consistent with World Bank benchmarks for a “good investment” of health resources in low-income countries. With an international commitment to finance the vaccine, the global community can begin to assure a sustainable, affordable supply of vaccines as early as 2007.

PneumoADIP analyses suggest that, with a firm commitment from donors and countries, it should be possible to get early access to life-saving pneumococcal vaccines and achieve sustainable supply at affordable prices. PneumoADIP is working with industry, governments, international agencies, and non-government organizations to develop a business model to link vaccine demand and supply, and permit the accelerated introduction of pneumococcal vaccines in low income countries.